The Global HPV
Vaccines Market size is segmented on the basis of product type, application,
and region. A vaccine used to prevent genital warts, anal cancer, cervical
cancer, vulvar cancer, and vaginal cancer caused by certain types of human
papillomavirus (HPV).
It is also used to prevent
lesions that are caused by those viruses and that can lead to anal, cervical,
vulvar, or vaginal cancer. Also called human papillomavirus vaccine.
Human papillomavirus (HPV) causes
cervical cancer, which is the fourth most common cancer in women, with
apredictable 266,000 deaths and 528,000 new cases in 2012. A large majority
(around 85%) of the global load occurs in the less developed regions, where it
accounts for almost 12% of all female cancers.
Get Details of HPV
Vaccines Market Report at :
https://www.millioninsights.com/industry-reports/human-papillomavirus-hpv-vaccines-market
HPV vaccine is an inactivated
(not live) vaccine which protects against four major types of HPV. These
include two types that cause about 70% of cervical cancer and two types that
cause about 90% of genital warts. HPV vaccine can prevent most genital warts
and most cases of cervical cancer.Human papillomaviruses (HPVs) are a group of
more than 200 related viruses. More than 40 HPV types can be easily spread
through direct sexual contact, from the skin and mucous membranes of infected
people to the skin and mucous membranes of their partners. They can be spread
by vaginal, anal, and oral sex. Other HPV types are responsible for non-genital
warts, which are not sexually transmitted. There is no treatment for HPV
infection, but the conditions it causes can be treated.
Based on type, the HPV vaccine
market size is classified into Low risk HPVs, and High risk HPVs.Low risk HPVs,
which do not cause cancer but can cause skin warts, precisely known as
condylomata acuminate, are found on or around the genitals and anus. For
example, HPV types 6 and 11 cause 90% of all genital warts. HPV types 6 and 11
also cause recurrent respiratory papillomatosis, a disease in which benign
tumors grow in the air passages leading from the nose and mouth into the lungs.
High-risk HPVs which can cause
cancer. About a dozen high-risk HPV types have been identified. Two of these,
HPV types 16 and 18, are responsible for most HPV-caused cancers. On the basis
of vaccines, the global market size is classified into bivalent and a
quadrivalent vaccine. Both vaccines are highly effective in preventing
infection with virus types 16 and 18, which are together responsible for almost
70% of cervical cancer cases globally. The vaccines are also highly effective
in preventing precancerous cervical lesions caused by these virus types.
The quadrivalent vaccine is also
highly effective in avertinganogenital warts, a common genital disease which is
practically always caused by infection with HPV types 6 and 11. Data from
clinical trials and initial post-marketing surveillance conducted in several
continents show both vaccines to be safe.On the basis of application, the HPV
vaccines market size is classified into pediatric, adult, and others.
Get Sample Copy of
HPV Vaccines Market at: https://www.millioninsights.com/industry-reports/human-papillomavirus-hpv-vaccines-market/request-sample
Geographically, the HPV vaccines
market size is segmented into North America, China, Europe, Japan, India, and
Southeast Asia.North America and Europe accounts for the maximum market share
of the global HPV vaccines market and is expected to grow at highest CAGR
during the forecast period. This is due to the governments from major countries
of these regions having publicly funded HPV vaccination.
The key players in the HPV
vaccines market include Astellas Pharma Inc, CSL Limited, Emergent
BioSolutions, Inc, GlaxoSmithKline, Johnson & Johnson, MedImmune, LLC,
Merck & Co, Pfizer, Sanofi Pasteur, Serum Institute, and India Pvt. Ltd.
No comments:
Post a Comment